#### REMARKS

Reconsideration is requested.

Claims 1-74, 76-78 and 80 have been canceled, without prejudice, to advance prosecution.

The recitation of the claimed complements have been revised to recite the specific sequences, and claim 81 has been amended to recite the specific sequences which were part of the claims from which the unamended claim depended. Claims 86 and 87 have been amended to further identify the recited type- and subtype-specific amino acid residues. Claims 86 and 87 recite the inclusion of at least 12 contiguous nucleotides, which finds support, for example, at page 8, line 2, of the specification. No new matter has been added. The amendments are not believed to raise new issues requiring further search and/or consideration. New claims have not been added. Entry of the claims will, at a minimum, reduce the issues for appeal, as described below. Entry of the amendments is requested.

The Examiner is again requested to return a completely initialed copy of page 1 of PTO 1449 Forms which were filed May 4, 2001, and of which a partially initialed copy was received with the Office Action of October 6, 2003. Specifically, the Examiner has executed the entirety of the Form and included her initials in the column to the left of the listed "U.S. Patent Documents" and "Foreign Patent Documents". The Examiner has not however included her initials in the left column next to the listed "Other Documents". The applicants last made a similar request on September 2, 2004 and included a copy of the previously-received PTO 1449 Form for the Examiner's information. Return of a completely initialed copy of the PTO 1449 Form is requested.

Claims 75, 79 and 81-87 are pending. Upon entry of the present Amendment, claims 75, 79, and 81-87 will be pending.

The Section 112, second paragraph, rejection of Claims 75, 79 and 81-87 is obviated by the above amendments. Entry of the present Amendment will, at a minimum, reduce this issue for appeal. The amended claims do not refer to the previously objected-to "at least 5 nucleotide" although the applicants believe the unamended claims are definite in this regard. Moreover, the claims have been amended to refer to "the" complement of specific sequences, which is believed to obviate the Examiner's concerns regarding the recitations of complements in the unamended claims.

The Examiner is urged to appreciate that the nucleotides encoding the amino acids recited in claim 86 and 87 are not "random ... polynucleotide primers" as suggested by the Examiner on page 2 of the Office Action dated April 11, 2005. Rather, the recited amino acids were identified as amino acids unique to the claimed HCV sequences and which are not present in any of the amino acid sequences identified prior to the filing of the priority application. The identification of the recited amino acids involved alignment of multiple HCV amino acid sequences, including sequences of the art, and screening for amino acids present in the HCV sequences of the present invention but not present in prior published HCV sequences. See, Figures 2, 4 and 6 of the present application.

The recited "12 contiguous nucleotides" will be understood by one of ordinary skill in the art to require, regardless of the reading frame, a fragment of at least 3 consecutive amino acid sequences, of which there is one of those specified in claims 86

and 87. The remaining nucleotides encoding the additional at least 2 amino acids are also not random as they are (i) part of a sequence encoding a HCV polyprotein and (ii) occur at a specified position in the HCV sequence relative to the sequence encoding the amino acid specified in claims 86 and 87 (i.e., at least 12 contiguous nucleotides).

The at least 3 (and up to at least 4) amino acids encoded by the polynucleic acids of claims 86 and 87 are necessarily encoding a part of at least 3 (and up to at least 4) consecutive amino acids of an HCV polyprotein of which at least 1 amino acid is unique to the HCV type or subtype as specified in claims 86 and 87. There is the possibility of 2 consecutive or non-consecutive amino acids unique to a given HCV type or subtype in the same fragment, e.g., V2652 and Q2653 for HCV type 7, or Q2752 and D2754 of HCV type 11.

The claims are submitted to be definite. Entry of the above and withdrawal of the Section 112, second paragraph, rejection of claims 75, 79 and 86-87 are requested.

The Section 112, first paragraph "written description", rejection of claims 86 and 87 "and claims 81-85 in as far as they read on [sic, depend from ?] claims 86 and 87" is obviated by the above amendments which have been made in response to the Examiner's statement on page 3 of the Office Action dated April 11, 2005, that "Claims directed to these specific SEQ ID NO's [SEQ ID NO: 1, 3, 5 etc. odd numbers to 105, and sequences encoding SEQ ID NO:107-207 which correspond to specific portions of HCV genomic sequences that fall within certain subtypes] would meet the written description provisions of 35 USC 112, first paragraph." Moreover, as the Examiner has apparently based, at least in part, the Section 112, first paragraph, rejection on the alleged indefiniteness of claims 86 and 87 (see, page 2, last paragraph, of the Office

Action dated April 11, 2005), and the Section 112, second paragraph, rejection has been obviated by the above, withdrawal of the Section 112, first paragraph, rejection is requested.

Entry of the present Amendment and withdrawal of Section 112, first paragraph "written description", rejection of claims 81-87 are requested.

The Section 102 rejection of claims 81-87 over Houghton (U.S. Patent No. 5,350,671) is obviated by the above amendments. The amended claims do not refer to the "short polynucleotide sequences" which are believed to have been the basis for the rejection. See, page 3 of the Office Action dated April 11, 2005.

Attached is a 24 page comparison of relevant parts of the sequence of Figure 66 of the cited Houghton et al reference as compared with Figures 2, 4 and 6 of the present application. The attached further illustrates that the sequence of Houghton et al is identical to the HCV sequence occurring on top of each of the applicants sequence alignments. The Examiner will also appreciate that for the NS5B region, the amino acid numbering of Houghton et al differs with 1 integer from the amino acid numbering in Figure 6 of the present application. That is, for example, in claim 86, S2645 is listed as an amino acid unique to type 7, whereas the closest S in the NS5B sequence is Houghton is at position 2646. The numbering of the claims has been clarified by reference to Figures 2, 4 and 6.

Entry of the present Amendment and withdrawal of the Section 102 rejection are requested.

Maertens et al Appl. No. 08/836,075 Monday, June 11, 2005

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned in the event anything further is required in this regard.

Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

Ву:

Reg. No. 36,663

BJS:

901 North Glebe Road, 11th Floor

Arlington, VA 22203

Telephone: (703) 816-4000 Facsimile: (703) 816-4100




FIG.66A

STATE OF THE PARTY	_	MSTNPKPOKKNKRNTNRRPODVKFPGGGQIVGGVYLLPRRGPRLGVRATR
HCV1 HCV-J	1a 1b	MSTNPKPQKKNKRNTNRRPQDVKFPGGGOIVGGVYLLPRRCPRICTER TOP
BNL1 BNL2 CAM1078	1d 1d	R-TXXXXXX-XXXXXX-X-XXXXX
FR2	le 1f	A-
HCJ6 HCJ8 CH610 NE92 BNL3 FR4	2a 2b 2c 2d 2e 2f	R-T
HCVTR	3b	LRQTLV-
DK13 CAM600 GB809 BNL7	4d 4e 4e 4k	R-TM
BE95	5a	R-TM
HK2	6a	LR-TT
FR1	7a	LR-TM
VN4 VN13	8a 8b	LR-TI
VN12	9a	LR-TM
NE98	10a	LR-TXVVV-

		TO THE PROPERTY OF THE PROPERT
Figure 2 -	continu	KTSERSOPRGRROPIPKARRPEGRTWAQPGYPWPLYGNEGCGWAGWLLSP-100
		KIZEKZAPKAKUAI II KAMM ESTITUTE
	,	51 KTSERSOPRGRROPIPKARRPEGRTWAOPGYPWPLYGNEGCGWAGWLLSP
HCV1	la ·	KTSERSQPRGRRQPIPRARRIEGRIMAGE
	1b	XX
HCV-J	1d	X-XSX-XS
BNL1		DQSD-XXH
BNL2	1d	EE
CAM1078	1e	AA
FR2	1f	
		LLL
нсј6	2a	- OR VO CV
	2b	D-ST-KS-GK
HCJ8	2C	
CH610		
NE92	2d	
BNL3	2e	LL
FR4	2f	
****		KQ-HLSRSKKL
HCVTR	3b	KO-HLSKSK-
HCVIK	5.5	
	4d	QLS
DK13		
CAM600	4e	
GB809	4e	XX
BNL7	4 k	·
		ALQ-TS-GAL
BE95	5a	
BE 9 J		
	6а	Q_QH
HK2	0a	
FR1	7a	
•		V-HQT
VN4	8a	V-NQ1
VN13	8b	V-HQ1
AMID	· · ·	
	9a	AV-QNQ
VN12	70	·
د		SRTS
NE98	10a	

10a

NE98

Figure 2	- conti	23/74
		RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA
HCV1 HCV-J	la lb	101 RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA
BNL1 BNL2 FR2	ld ld lf	N NS-T
HC-J6 HC-J8 CH610 NE92 BNL3 FR4	2a 2b 2c 2d 2e 2f	NHVVV TH
HCV-TR	3b	vv
GB116 DK13 CAM600 GB809 G22 GB549 GB438 BNL7	4c 4d 4e 4f 4f 4g 4h 4k	VV -X-XNXVV NVV VV VV
BE95	5 <b>a</b> .	NNKG-IV
HK2	6a	HNV-A-
FR1	7a	NNVL-GVL-GV-A-
VN4 VN13	8a 8b	NNXXXIE
VN12	9a	D-X-NXV-AE

	•	
Figure 2	- conti	-I AUCURUS ERCUMVATON ROCCES
		LAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL-200
HCV1	- 1	131
HCVI HCV-J	la	LAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL
BNL1	1b	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BNL2	1d	XT-HEAS-V
FR2	1d 1f	
r KZ	. 11	-XXGXXXXXXXXXXTI-HEAS-V
HC-J6	2a	
HC-J8	2b	FI-T-VAE-K-ISTG
CH610		
NE92	2c`	
BNL3	2d	
	2e	X
FR4	2f	
BNL4	2g	
BNL5	2h	
BNL6	2i	I
IICII MD	21	· -
HCV-TR	3b	A-GFFCGLEYT-TS
GB116	4	B
	40	-EAVISTVNYAS-V
DK13	4d	LNYS-V
CAM600	4e	AVITVNYAS-I
GB809	4e	AVI
G22	4f	AVI
GB549	4g	AVI
GB438	4h	AVIVROUV NO T
BNL7	4 k	I-F
BNL8	4 k	I
BNL9	4 k	THUI ME Y
BNL9	4 k	IIXX
BNL10	4 k	IX
BNL11	41	II
	_	
BE95	5a	
*****	_	•
HK2	6a	AII
		·
FR1	7a	AITIK-AS-I
TD:4	_	·
VN4	8a	XXIXX-X-X-X-XXTAHYT-KS
TATE O	•	
VN12	9a	-XAIIXTLNYA-KS
MEGO	10-	
NE98	10a	I-F

Figure	2 - cont	i med
_		YHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRD
		201
HCV-1	la	
HCV-J	1b	YHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRD
BNL1	īd	
BNL2	īd	
FR2	1f	
	-1	S-GK-IXIIPLL-X-I
HC-J6	2a ·	-M. m.p. manage
HC-J8	2b	-MT-DTWQLQA-VVEKVTIPVS-NVQQ
CH610	25 2c	-YAS-N-TWQLT-V-LENDNGTLH-IQV-N-VKH
NE92	2d	
BNL3		
FR4	2e.	-MAS-NWQLXVVERS-IIPVS-NI-VSQ -MAA-DWOLRVV
	2f	-MAA-DWQLRVVE-NSSGRFHIPIS-NI-VSK -MAS-NIWOMOG-VV
BNL4	2g	-MAS-NIWQMQG-VVELQKIPVNVNQ
BNL5	2h	-MSWQLKVVE-HQ-QIPVNVNQ -MSWQLFF-VV
BNL6	2i	-MSWQLEE-VVEWKD-TIPVNI-VSQ
HCVTR	3b ,	-VLS-GE-VLTTQ-STTVSTV-T
	,	
GB116	4 c	I
DK13	4d	LLLLLLAPY
CAM600	4e	
GB809	4e	IATENHLK-TSLAQH
G22	4f	
GB549	4 a	
GB438	4h	
BNL7	4 k	
BNL8	4 k	
BNL9	4 k	
BNL9	4 k	
BNL10	4 k	
BNL11		
GB724	41	
GD / Z4	4×	I
BBOE	_	
BE95	5a -	QILSAPS
HTCO.	_	
HK2	6a	LLDAMLLVDDR-TH-VL-IPN
FR1	7a	LS-NFETMLIKAELPVSL-VPN
VN4	8a	LETLL
	•	QASL-VPN
VN12	9a	LNGMLKTLTKLSASL-VQN
	**	WGIILTKLSASL-VQN
NE98	10a	-MS-GG-ILSTIPVSYVVS

26/74

_		
Figure 2	- conti	GKLPATQLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWT-300
	:	251 300
HCV-1	1a	GKLPATOLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWT
HCV-J	1b	SSI-T-TIVA-AMSYE-
	id	ASV-TXAIVXX-FM-XAM-H-
BNL1		ANV-TAAIVT-AFRMLYH-
BNL2	1d	ANA-IDEVVA-VFM-IGTS
FR2	1f	PGALTOGTMV-MG-M-AA-M-IVQHF
HC-J6	2 <b>a</b>	
HC-J8	2b	RGALTRST-V-MI-MAAVA-MILS-A-MVQNF
CH610	2c	PGTLTKGA-V-VI-MVALMIAA-AVIAQTF
NE92	2d	PGALTKGTTIIAFIA-M-AS-V-IIQH-KF
BNL3	2e	PGALTKGARAV-MVA-MIAA-A-IVA-KYF
FR4	2f	PGALTRGATI-MIA-MIAA-VAVVQY-TF
BNL4	2g	PGALTRGTTI-MVIVA-MIAA-VVIVOH-NF
BNL5	2h	PGALTRGTTI-AVFA-MS-F-MIQH-IF
BNL6	2i	PGAXTKGTII-AF
DIADO	21	I drawing i and i
HCVTR	3b	LGVTTASI-T-V-MARQAF-AAF-AT-
UCATY	30	INVITED TO THE PARTY OF THE PAR
CD116	4c	VGA-LESS-VMAVIGM-S-Q
GB116		LNA-LESVM-GIV-GQ
DK13	4d	AGA-LEPVMA-MIGLMQ
CAM600	4e	AGA-LEPVM-A-MGLMV
GB809	4e	VGA-LEPVMAVGLMQ
G22	4f	LGA-LESMV-M-TGIA-MRL
GB549	4g	VGA-LESMVMAVIGMR
GB438	4h	LGA-L-SV-Q-V-M-AI-H-GA-MVS-Q
BNL7	· 4k	IGA-LESS-VMAVIX-XGLM-S-R
BNL8	4 k	IGA-LESS-VMAVIGLM-S-R
BNL9	4 k	IGA-LESS-VMAVIGAM-S-R
BNL9	4 k	TAA-LESS-VMAVI-XGLM-SXQ
BNL10	4 k	IGA-LESS-V-VMAVIGLM-S-R
BNL11	41	LSA-LMSVVMASGAMQ
GB724	4x	VDA-LESFVMA
GB12,4	. 48	VDA-DESTV-III A
05	F -	LGAVTAPAV-Y-A-G-AAALMYRQ-A-
BE95	5 <b>a</b>	TCAA IABWA-I-W-G-WWWWWW
	_	
HK2	6a	ASTGFVA-A-VVSILAQ
	•	•
FR1	7a	SSV-IHGFVA-AFM-IIIR-KY-QV
		•
VN4	8a	AST-V-GF-K-V-IMA-AFMGLLRM-QV
		•
VN12	9a	ASVSIRGV-E-VA-AFMGLRMYEI
ATATE		
NE98	10a	PCAATAST-V-MM-XAALXG-SWRH-Q
NEJO	IVa	TOTALISM I A THE THE TYPE IT O DAILOR &

		シフ /	/ 7 A		
	contin			V ALVMAQLLRIPG	AILDMIAG
Figure 2 -			119	71.5	
HCV-1 HCV-J BNL1 BNL2 FR2	1a 1b 1d 1d 1f	TOGCNCSIYPGHITGHRMF V-DVS E V-DSXXX	<u>.</u>		
HC-J6 HC-J8 CH610 NE92 BNL3 FR4 BNL4 BNL5	2a 2b 2c 2d 2e 2f 2g 2h	V-E V-E V-E S-D V-D	- X - - -X		
HCVTR	3b	V-TVS			
GB116 DK13 CAM600 GB809 G22 GB549 GB438 BNL7 BNL8 BNL9 BNL9	4c 4d 4e 4f 4g 4h 4k 4k 4k	DAVDTDAETDV A-DDDDD	    		
BNL10 BNL11 GB724	41 4x	V-D DT			
BE95	5a	V-NSV			
нк2	6a	V-DTV	<b></b>		
FR1	7a	DXNXV			
VN4	8a	V-ET			
VN12	9a	A-DA	, <u>an <del>ai</del> ai</u>		
NE98	10a	V-D		•	•

(BULE 26)	SHEEL	SUBSTITUTE

SUBSTITITE SHEET (BIJLE 26)		ı	
CAM1078 FR2 FR16 FR2 FR16 HC-J6 HC-J6 HC-J8 CCH610 NE92 BNL3 FR13 FR13 EB1 NZL1 NZL1 NZL1 HCV-TR GB358 DK13 CAM600 GB809 HPCCOREZB	HCV-1 HCV-J BNL1	Figure 4. ( Isolate	
110777554444444433322222222222 1000000000000000000000000	1a 1b	Core/E1	
10/60 12/60 66 114 118 76 128 28 28 28 46 46	, N	SEQ SEQ	
	MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATR	MSTNPKPOKKNKRNTNRRPODVKFPGGGOIVGGVYLLPRRGPRLGVRATR	FIG.66A

00	00	ب	!	!	į		!	!	!	!	į.	!	!	!	!		•	!		!	ļ	1 !	i				ì	1	<u> </u>	ļ	!	!	1	i i	
KTSERSQPRGRRQP1PKARRPEGRIMAQPGYPWPLYGNEGCGWAGWLLSP-100	51 core-V	KTSERSOPRGRROPI PKARRPEGRTWAQPGYPWPLYGNEGCGWAGWLLSP	1 M	X	HXX-QSÖ	XS		MSS	TTT	DST-KS-GK	DTT-KS-GR	83	L	LL	X-QLD-XTT-KS-GRL			KQ-HLSRSKQ-HLL					ן היים ביים ביים ביים ביים ביים ביים ביים		1				,			ONO-	-\-\T-\O-\-		·
0	ID ID			(7	9	10/6	12	99	1				14	18	16							1	28					•		46	44	48	42	20	104
9	1 y bc	1 a	1. 1.	1q	1g	1e	].F	1a	2 a	2p	2c	2d	2e	Z£	2k	رب در	ນ (ຕ (ຕ	36	4c	49		46	4	4.	4. C•	4.3	4	Sа	6a	7a	70	79	g S	10a	11a
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )	מסדמה	HCV-1	HCV-J	BNL1	BNL2	CAM1078	FR2	FR16	HCJ6	HCJ8	CH610	NE92	BNL3	FR4	FR13	1 K	NZL1	HCV-TR	GB358 ·	DK13	CAM600	GB809		HPCCOREEZA	HPCCOREZB	HPCCOREZC	GB724	BE95	HK2	VN13	VN4	VN12	FR1	NE98	FR19
													SI	JB	ST	T	JŤE	SI	HEI	ET	(Rl	JLE	20	6)											

RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA	RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA	X	X		^N	$$ $\mathbf{Y}$	^^^	/16XXXXXXX-X	AX	<b>H</b>		AA	AAXXXXXXX	AAA		\lambda \l	1	-^-\T-9XXXXXXX-		XX	-^XXXXX	N	X
SEQ	1	۲3	10/	12	99			14/	18	96							28		•	46	4. C	42	20
Туре		19 19	19 H	] <del>[</del>	ე <b>ქ</b> ე გ	2p	U 7	2 K 2 G			3p	4, 4 O L	. 4. 2 9	4e	4£	4 4 7	4 k	5a	<b>6a</b>	7a 1	ט ל	9 8 9 8	10a
Isolate	HCV1	BNL1	BNL2 CAM1078	FR2	FR16 HC-J6	HC-J8						GB116					BNL7	BE95	HK2	VN13	VN4	FR1	NE98
			•				•				_ •		\			,	•						


LAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL-200	51 200	VRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVR	N-S4XT-HE	-XGXXXXXXXXXXTT	Q-F-D- 	VVE	STST-XVSTSSTS-X-TSTS	VE-KDTGDS 	V-XVE-R	HEN-X-X-II-II-II-II-II-II-II-II-II-II-II-II		- A	1		EHY	- 1	1	XHI	I	11 X N - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		TATAI	T-HXHV	AVI	KI	I-SL-HANI	i
	SEQ I	E.I.	4ı α	12 -x	99		į	ì	16	18	0.7	. 92 20	76		İ		•	ध्य i	·	i	i i	i i		i i		დ დ 2 4	
	Type	1a 1b				2, C4 C2, C4	20 50	0 TO 10 KN	1 C3	77 C	אני סל	. 21	X	ე გ კ	. 4 . 6	4a		4. 4. O C			4, 4 O (	1. 4. D A1	4 £	4. 4 Q.'C	4 X	4 4 X X	4 k
	Isolate	HCV1 HCV-J	BNL1 RNL3	FR2	FR16	8510H	CH610						HE FR13		7.4 1			GB116	GB358	DK13	CAMEOU	GB00912 CAMG22	CAMG27	GB549	BNL7	BNL8 BNL9	BNL10

I-SVVYVS-I	VPYTTARG-	
IXI	AII	

80 4447 80 4867

4k 41 5a 5a 6a 7c 7d 9a 10a

BNL11 BNL12 BE95 BE100 HK2 VN4 VN12 FR1 NE98




BNL12 GB724 BE95 BE100 HK2 VN4 VN12 FR1

GKLPATGLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWT-300	1 300	DLLVGSATLCSALYVGDLCGSVFLVGQLFTFISPRRHW	XX-FMXA	VT-AFRM	VA-VEM-I		RGALTRST-V-ML-MAAVA-MLDS-A-MVQNF DOMI WV	A-V-VI-II	TTIIAFIA-M-AS-V-II	ARAV-MVA-MIAA-A-IVA-	-ATI-MIA-MIAA-VAVV	TTI-MVIVA-MIAA-VVIV	   		-TI-AFIVAIMIAA-VVIV		T-V-MARQAF-	VMA			888-VM4-AV	\-IMA	VMGI	-VMAMIGL-	-VMAVGIM	MTGIA-	MTTTM-N-K	MMMAMA	-VMAAAAAA	X-X-XIXWX-S	S-VMMMNI		1	S-V-VMAVII
GKLPATOLR	V4	GKLPATQURRHI SST-T-TTV	ASV-TXAI		ANA-IDEV	PGALTOGT	RGALTRST	ABATTEDA DGAT.TKGA	: ⊢	PGALTKGA	PGALTRGA	PGALTRGT	PGALTRGT		PGALTEGS	VGATTASI-S-V	LGVTTASI-T	PGA-LESF	MDA-LESE.	PNA-LESM	•	TCA-TEG-	LNA-LES	AGA-LEP	VGA-LEP	LGA-LESMV	IGA-LESM	VGA-LESMV	LGA-L-SV-Q	1	1	SE	1	1GA-LES
	SEQ.	) 1	4	æ	12					16	18	20	24	97	92														1	30	32	34	36	ž
	Туре	1a 1b	i p	1q	1.E	2a	Ω (	) (	מ מ	2 <b>e</b>	2£	2g	ųź	.T.	77 X	3a	3p	4a	<del>م</del> .	4p	<b>4</b> Δ	4, 4 O (	40	4e	4 e	4 £	4 £	<u>4</u> g	4h	4 k	4 k	4 ×	4 ×	4 K
	Isolate	HCV-1	BNL1	BNL2	FR2	HC-J6	HO-JB	CHOTO	NE92		SU FR4			•						21	GB116	() GB213	DK13	CAM600	GB809-2	CAMG22	CAMG27	GB549	GB438	BNL7	BNI'8	BNI.9	BNL10	BNL11

LSA-LMSVVMASGAMQ VDA-LESFVMAV	ASTGEVA-A-VVSILAQ AST-V-GE-K-V-IMA-AFMGLLRM-QV ASVSIRGV-E-VA-AFMGI	SSV-IHGFVA-AFM-IIIR-KY-QV PCAATAST-V-MM-XAALXG-SWRH-O
4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	444	57.42 52.53
ት 4 ቢ ቢ ሲ 4 ኧ ቁ ቁ ቁ	27 D	10a 52
224 00 00	۲۷	æ

TOGCINCS I YPGH I TGHRMAWDMMNWSPTTAI VMAOI I 9 I DOAI'I DMIAG		301	MANCOLLEGICANA 	1		XXXS			X				X=			X 1 * 0 *	9.II	SA			V2	AV		AV	,									1 1 1 9			
	, וכור		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Ä	H	V-D	Q-D	五	V-E	V-E	V-D	V-E	V-E	S-D	<u>-</u> -	V-D	٧-٦	V-T		Q	<u></u> Ω	9	<u> </u>	1	7	Q	D	<u>日</u>	<u> </u>	0-1	7	P	A-D	P	D	<u> </u>	<u>V-</u> D
	SEQ	ת ה		<b>ታ</b>	8	12						16	18	20	24	9/																8	32	34	9	38	0
	Type	1a	1b	1d	1q	<del>,</del>	ry W	ეე	, 2	N C							3a	ЗЪ	<u>4</u> a	ر م	φ.	ပ္	ပ	<u>o</u> :	ğ	ψ	<b>O</b>	44	44	b	4ĥ					س	T
	Н	•																	-		•	•	•	7.	٧.	7.	7.	4.	4	4	4	4	4	ਹਾ ।	毋 ·	ਹਾ •	ਹਾਂ
	Isolate	HCV-1	HCV-J	BNL1	BNL2	FR2	HC-J6	HC-78	CH610	283	NE92	S BNI3	IB:	BNI BNI B	TI BNI'S	III FR13	S BR36	HCVTR	77 ET	S GB809-4	77 VI	9T 195 E2	(98215 (98215	GB358	DALS	CAM600	60899	CAMG22	CAMG27	GB549	GB438	BNL7	BNL8	BNL9	BNL10	BNLLL	PINTTS
																																		٠			



4 4 4 8 5 2 2 3

44 ж 5 а 6 а 7 с 1 о а

GB724 BE95 BE100 HK2 VN4 VN12 FR1 NE98


i															
FIG.66B			769				٠					-			
VQPEKGGRKPARLIVFDIGVRVCEKMALYDVVT-2600 PGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVFE	ino acid alignment	(9)	STVTBSDIRTEEALYQCCDLDPQARVAIKSLTERLYVGGPLTNSRGENCG			NVK-Q	XXV-XSK-0	RA-S-PEE-H	M	S-PETHMI	SIA-S-PETH	-S-SI-NSN			
NEVFC SFQYS	NS5B ami	e SEQ	j		50.0					70	72	78	9		82
DTTIMAK AVMGSSY(	6. NS	Type	다. 다.	125	7 17	1 0 r	1£ 19	28 25	1 67 C	7 7 Q 0	2£	2k 7 c	. w .	ນ ເກ ໝ ໝ	3b 3g
KLPLA	Figure	Isolate	HCV-1	2TY4 BNL1	BNL2 FR17	CAM1078	FR16	HC-J8	ARG8	ENESS BNL3	S STE ER4 BNL5	HEE 133	BR34	a BR33	(92 T9) Pak64

KVEVE-E-E-KTAMHK-DI	F - F - F - F - F - F - F - F - F - F -						IV-N	TXUX-KV	FIFT - F		TO-XHW		I		00-YYM0	00-YIM0			SOXWO-WIW		HO-NM	R		
											84	٥	88	,	•	90	35	94	96	98	100	102	106	
4 0	Δ <del>,</del>	4c	4 C	4 e	4 £	4 q	4h	54i	<u>4</u> -	4. 	4 k	41	4 m	5a	5a	7a	.7c	79	98	10a	11a	11a	11a	
GB48	GB116	GB215	GB358	GB809	CAMG22	GB549	GB438	CAR4/1205	CAR1/501	EG13	BNL8	BNL12	EG81	BE95	CHR18	VN13 .	VN4	VN12	FR1	NE98	FR14	FR15	FR19	
٠.		٠		٠.	-			.i .								ST	T	UT	E S	SHE	ET	(F	lUL	E 2

	YRRCR-2700 2695 ASGVLTTSCGNTLTCYIKARACRAAGLQDCTMLVCGDDLVVICE	RASGVLTISCGNTLTCY I KARAACRAAGI.ODCTMI.VCGDDI.VVTC		K						Ė	WIXIIAPS-	MIKIV-PV	VNIVAP-	-IK	-IIKIVAP	-IVLKIVAP	IVLKIVAPI		IVMIDAP	FITARNPDF	RSPDF	FITAKRNPDF	KKKSKNS		
Į	SEQ Y		•	•	. 4.	. 99	. 86	. 25	64	. 86	•	•	•	•		72 .	74	. 8/	. 00	•		•	1		
	Type S	1a	1b	1c	1d	1d	1d	1e (	1£ (		2a	<b>5</b> p	2C	2d		2£				3a	3a	3a	3p		
	Isolate	HCV-1	HCV-J	2TY4	BNL1	BNL2	FR11	CAM1078	FRZ	FR16	HC-J6	. HC-J8	ARG8	NE92	E BNI.3	FR4	I BNI 5	I FR13	FR18	H BR34	H BR36	<ul><li>BR33</li></ul>	ខ្ពះ	F PAK64	26)
				·					. •				`											٠.	

44-44-44-44-44-44-44-44-44-44-44-44-44-	
- R	
888 9999999999999999999999999999999999	
44444444444444444444444444444444444444	
GB48 GB116 GB315 GB358 GB358 GB369 CAR4/1205 CAR1/501 EG13 BNL8 BNL8 BNL12 EG81 BR51 EG81 BE95 CHR18 VN13 VN13 VN13 FR14 FR15 FR19	
SUBSTITUTE SHEET (RULE)	26)

			EDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGRR_2RD
Isolate	Type	SEO 1	NOOT WINDS THE PROPERTY OF THE
	1		2745 2757
HCV-1	1a		SAGVQEDAASLRA
HCV-J	1b	•	T
BE90	1p		Λ
BNL1	1d	54	
BNL2	1q	26	EΛ
FR17	1d	58	-XENV
CAM1078	1e	29	-V-TT-V-
FR2	1£	64	IE-XXPS
FR16	1g	89	
HC-J6	(2)		-Q-TEERN
HC-JB	<b>5</b> p		-Q-NEERN
NE92	5d		-Q-TEERN
S BNL3	2e	70	-QEDRN-
BFR4	2£	72	-Q-AEERNV
ST BNI'S	Sh	74	-Q-TEERNV
II FR13	2k	78	-Q-TER-ENNP
III FR18	21	80	-Q-TEERNV
S BR34	3а		
H BR36	3а		1
11 BR33	3a		
бг (R	3p		-CER-A
PAK64	3g	82	-CX-D-EDRAALR
26			



```
GB48
GB116
GB116
GB116
GB116
GB116
GB215
GB215
GB215
GB358
GB309
GB309
GB309
GB438
GB438
GB438
GB438
GB438
GB438
GB438
GB438
GAR4/12054i
CAR4/12054i
CAR1/501 4j
GB195
GB195
GB195
GB196
GB196
GB297
GB197
G
```

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

•	
☐ BLACK BORDERS	
☐ IMAGE CUT OFF AT TO	P, BOTTOM OR SIDES
☐ FADED TEXT OR DRAW	'ING
BLURRED OR ILLEGIBI	LE TEXT OR DRAWING
☐ SKEWED/SLANTED IMA	AGES
☐ COLOR OR BLACK ANI	WHITE PHOTOGRAPHS
GRAY SCALE DOCUME	NTS
☐ LINES OR MARKS ON O	PRIGINAL DOCUMENT
REFERENCE(S) OR EXE	IIBIT(S) SUBMITTED ARE POOR QUALITY
П отнер.	

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.